机器人辅助肾部分切除术治疗临床T2期肾肿瘤的多中心分析
该多中心回顾性研究分析了298例非转移性cT2期肾肿瘤患者接受机器人辅助肾部分切除术(RAPN)的围手术期、功能和肿瘤学结局。中位肿瘤大小7.6 cm,中位RENAL评分9,中位缺血时间25 min,中位估计出血量150 ml。术中并发症5.4%,术后并发症22%(5%为Clavien≥3级)。中位随访12个月,8%切缘阳性,10例死亡,25例复发/转移。结论认为对选择性的cT2肾肿瘤,RAPN可安全实施且结局可接受。
要点
- cT2肾肿瘤行RAPN中位肿瘤7.6cm,中位缺血25min,出血150ml。
- 术后并发症22%,其中Clavien≥3级占5%;术中并发症5.4%。
- 较低RENAL评分和病理pT2期与术后并发症风险降低相关。
核心结论
- 对选择性的cT2期肾肿瘤,机器人辅助肾部分切除术可安全实施,围手术期、功能和肿瘤学结局可接受。
研究设计与样本
- 回顾性分析多中心、多国数据集(ROSULA协作组),纳入298例接受机器人手术治疗的非转移性cT2期肾肿瘤患者。
主要发现
- 中位肿瘤大小7.6(7-8.5)cm,中位RENAL评分9(8-10),中位缺血时间25(20-32)min,中位估计出血量150(100-300)ml。
- 多变量分析显示较低RENAL评分(OR 0.46,95%CI 0.21-0.65,p=0.02)和病理pT2期(OR 0.51,95%CI 0.12-0.86,p=0.001)对术后并发症有保护作用。
- 243个病灶(82%)为恶性,20例(8%)切缘阳性;中位随访12(5-35)个月,发生10例死亡和25例复发/转移。
- 单变量分析中,较高的pT分期可预测复发/转移的可能性(p=0.048);出院时肾功能显著恶化,但1年随访时保持稳定。
临床怎么用
- 对于经过选择的cT2期肾肿瘤患者,可考虑采用机器人辅助肾部分切除术以保留肾功能。
- 术前RENAL评分和术后病理pT分期有助于评估术后并发症风险。
局限性
- 本研究的主要局限性为回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While partial nephrectomy (PN) represents the standard surgical management for cT1 renal masses, its role for cT2 tumors is controversial. Robot-assisted PN (RAPN) is being increasingly implemented worldwide. OBJECTIVE: To analyze perioperative, functional, and oncological outcomes of RAPN for cT2 tumors. DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of a large multicenter, multinational dataset of patients with nonmetastatic cT2 masses treated with robotic surgery (ROSULA: RObotic SUrgery for LArge renal mass). INTERVENTION: Robotic-assisted PN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients' demographics, lesion characteristics, perioperative variables, renal functional data, pathology, and oncological data were analyzed. Univariable and multivariable regression analyses assessed the relationships with the risk of intra-/postoperative complications, recurrence, and survival. RESULTS AND LIMITATIONS: A total of 298 patients were analyzed. Median tumor size was 7.6 (7-8.5) cm. Median RENAL score was 9 (8-10). Median ischemia time was 25 (20-32) min. Median estimated blood loss was 150 (100-300) ml. Sixteen patients had intraoperative complications (5.4%), whereas 66 (22%) had postoperative complications (5% were Clavien grade ≥3). Multivariable analysis revealed that a lower RENAL score (odds ratio [OR] 0.46, 95% confidence interval [CI] 0.21-0.65, p=0.02) and pathological pT2 stage (OR 0.51, 95% CI 0.12-0.86, p=0.001) were protective against postoperative complications. A total of 243 lesions (82%) were malignant. Twenty patients (8%) had positive surgical margins. Ten deaths and 25 recurrences/metastases occurred at a median follow-up of 12 (5-35) mo. At univariable analysis, higher pT stage was predictive of a likelihood of recurrences/metastases (p=0.048). While there was a significant deterioration of renal function at discharge, this remained stable over time at 1-yr follow-up. The main limitation of this study is its retrospective design. CONCLUSIONS: RAPN in the setting of select cT2 renal masses can safely be performed with acceptable outcomes. Further studies are warranted to corroborate our findings and to better define the role of robotic nephron sparing for this challenging indication. PATIENT SUMMARY: This report shows that robotic surgery can be used for safe removal of a large renal tumor in a minimally invasive fashion, maximizing preservation of renal function, and without compromising cancer control.
引用
- Bertolo R, Autorino R, Simone G, et al. Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). Eur Urol. 2018. PMID: 29784191. doi:10.1016/j.eururo.2018.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。